Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD
China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...
Company
HutchMed to Divest 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has reached an agreement to divest its...
Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China
US-based medical device leader Boston Scientific Corporation (NYSE: BSX) has announced the market launch of...
Alphamab Oncology’s JSKN033 Advances to Phase III Trial for Platinum Resistant Ovarian Cancer
China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...
Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema
Sino-US firm Frontera Therapeutics, Inc. has announced that it has received approval from the US...
Johnson & Johnson’s Rybrevant Combo Approved by EC for First-Line NSCLC Treatment
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that the European Commission...
BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312/BG-C9074
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...
Novartis Announces Positive Results from Phase III STEER Study on SMA Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive topline results from the Phase III...
Xtalpi Inc. Partners with Amazon Web Services to Accelerate Life Sciences Innovation
Shenzhen-based QuantumPharm Inc., operating under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...
Jiangxi Jemincare Group Gets NMPA Approval for Prostate Cancer Drug JMX-2006
China-based Jiangxi Jemincare Group has announced that it has received clinical trial approval from the...
CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2219 in China
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the initiation of an investigator-initiated-trial (ITT)...
We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange
China-based We Doctor Holdings Limited, a subsidiary of Chinese internet giant Tencent Corporate Venture Capital...
Shinva Medical Instrument to Acquire Stake in Wuhan Zhongzhi Biotechnologies for IVD Expansion
China’s Shinva Medical Instrument Co., Ltd (SHA: 600587) has announced its intention to acquire a...
Hinova Pharmaceuticals’ HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer
Chengdu-based biotech Hinova Pharmaceuticals Inc., (SHA: 688302) has announced that it has received clinical trial...
CanSino Biologics’ Menhycia Receives Market Approval in Indonesia
China-based CanSino Biologics (HKG: 6185) has received market approval from the Badan Pengawas Obat dan...
CSPC Pharmaceutical Group Receives NMPA Approval for SYH9016 Clinical Study in Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
MicuRx Pharmaceuticals’ MRX-5 Receives FDA Orphan Drug Designation for NTM Infections
Sino-US firm MicuRx Pharmaceuticals Inc. has announced that the US Food and Drug Administration (FDA)...
Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced a significant licensing agreement with US-based...
CARsgen Therapeutics’ Satricabtagene Autoleucel Shows Positive Results in Phase II Study
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced positive results from its pivotal Phase...
argenx’s Vygart Hytrulo Approved in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
Holland-based argenx SE (NASDAQ: ARGX) has announced receiving another indication approval from Japan’s Ministry of...